Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Operating Expenses (2016 - 2025)

Altimmune (ALT) has disclosed Operating Expenses for 16 consecutive years, with $28.9 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 16.28% to $28.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $94.5 million through Dec 2025, down 8.39% year-over-year, with the annual reading at $94.5 million for FY2025, 8.39% down from the prior year.
  • Operating Expenses for Q4 2025 was $28.9 million at Altimmune, up from $20.9 million in the prior quarter.
  • The five-year high for Operating Expenses was $33.7 million in Q4 2023, with the low at $15.7 million in Q1 2021.
  • Average Operating Expenses over 5 years is $24.2 million, with a median of $23.9 million recorded in 2022.
  • The sharpest move saw Operating Expenses skyrocketed 108.7% in 2021, then decreased 26.11% in 2024.
  • Over 5 years, Operating Expenses stood at $27.3 million in 2021, then fell by 15.69% to $23.0 million in 2022, then surged by 46.45% to $33.7 million in 2023, then fell by 26.11% to $24.9 million in 2024, then rose by 16.28% to $28.9 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $28.9 million, $20.9 million, and $22.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.